$272M CooperSurgical settlement highlights nationwide fertility‑sector liability risk

The Free Egg Freeze Model and Its Appeal to Tech Workers

Cofertility closed a $7.25 million Series A in April 2025, led by Next Ventures and Offline Ventures with Initialized and Gaingels participating, bringing total funding to $16 million. The round caps a three-year sprint in which the Los Angeles startup turned a "split" donation model into a national marketplace: women freeze eggs for free by donating half the yield to intended parents, who cover retrieval costs and Cofertility's coordination fee. The mechanic has forced incumbents to layer financing guarantees and platform upgrades atop their clinic networks, while regulatory whiplash and insurance gaps keep the sector's growth tethered to private capital.

Lauren Makler co-founded Cofertility in 2022 with health-tech investor Halle Tecco after her own fertility scare rewrote her understanding of the market. In 2018, at 28, Makler was diagnosed with multicystic peritoneal mesothelioma — a rare abdominal disease striking two in one million people annually — and faced surgeries that threatened her ovaries. Her sister froze eggs as a backup. "I got to live my life with the gift of frozen eggs," Makler said. "I got to make that decision about my career without the pressure of my biological clock." When Makler later explored egg donation for herself, she found a system she called "antiquated and outdated." Donors were paid thousands, with premiums for heritage, education, and talent. "They're literally surge pricing for egg donors," she said, a phrase that carried weight from her years building Uber Health.

Cofertility's split program screens donors against FDA and American Society for Reproductive Medicine guidelines: ages 21 to 34, anti-Müllerian hormone levels above 2.0, no disqualifying genetic conditions. About 55 percent of donors hold graduate degrees, Makler told TechCrunch. For women who don't qualify, Cofertility offers a paid cycle, roughly $16,000 for one cycle and ten years of storage in New York City, compared with an industry average of $17,773 for a single cycle and five years of storage, per FertilityIQ. The economics land hardest on tech workers. Career focus and delayed marriage push family planning into the thirties, exactly when egg quality declines and out-of-pocket costs peak. A single cycle with medications runs $10,000 to $15,000, plus $300 to $1,000 annually for storage, per GoodRx data cited by Healthcare Brew. Most employer plans exclude elective freezing. Preliminary data from the Society for Assisted Reproductive Technology show nearly 40,000 people froze eggs in 2023, yet only about half of IVF cycles resulted in live births.

National Scale and the Hiring Surge

The model does not work unless it operates at national scale. Cofertility matches egg donors with intended parents across state lines: "at any given time, we have hundreds of donors that are available for intended parents," Makler told TechCrunch in April 2025, contrasting that pool with the handful most clinics can offer locally. By June 2025, Healthcare Brew reported the program had matched intended parents with donors "well into the quadruple digits." That volume only exists because the platform aggregates supply and demand nationwide, not within a single metro area.

A two-sided marketplace of that breadth requires outreach teams who can engage donors and recipients across time zones. The company's growth timeline makes the case: founded in 2022, it raised the Series A in April 2025. Capital that size buys headcount, and the product logic dictates where those heads sit. Meela Imperato, Cofertility's head of marketing and brand, put it directly in a 2025 Carnegie Mellon profile: "As the company scales, she brings in specialists to expand and refine the approach." The specialists she referenced follow the users.

Elective egg-freezing cycles nearly quadrupled between 2014 and 2021, hitting nearly 40,000 in 2023 alone, per preliminary SART data cited by Healthcare Brew. Cofertility's donors — roughly 55 percent hold graduate degrees, according to Makler — are drawn from that same national cohort of career-focused women in their 20s and early 30s who cannot afford $10,000 to $15,000 per cycle. Reaching them requires digital-first acquisition funnels, not campus recruiting events in one city.

The same logic applies to the recipient side. Intended parents cover retrieval costs and Cofertility's coordination fee but avoid direct donor compensation, lowering their out-of-pocket expense relative to traditional donation. That value proposition travels across state lines; the company's "baby guarantee" for recipients is a national promise. Delivering on it means coordinating clinics, legal agreements, and logistics in whatever jurisdiction the parties inhabit, work that is inherently distributed.

Competitors face the same geometry. Kindbody's next-generation platform announcement emphasized "improving outcomes, accelerating affordability and intelligence in reproductive care" across its network. Fairfax Cryobank and IVI RMA North America partnered to expand donor-sperm access "across key European markets." California Cryobank launched a new guarantee for its donor-egg bank. Each move presupposes a workforce that can operate without geographic tether.

The research does not disclose Cofertility's internal remote-work policy or a headcount breakdown by role. But the structural evidence is consistent: a marketplace that matches hundreds of donors with thousands of recipients across the United States, backed by $16 million in venture capital and led by a founder who built Uber Health on a distributed-driver model, will hire outreach specialists where the users are. That is not a policy choice. It is a product requirement.

Competitors Scramble to Respond

Kindbody moved first and loudest. In a PR Newswire announcement the company unveiled what it called a "next-generation fertility platform" built to improve outcomes, accelerate affordability, and embed intelligence across reproductive care, language that mirrors the exact pain points Cofertility's split model exploits. The platform rollout coincided with a financing partnership with Future Family, a fertility-focused lender, to offer patients payment plans that undercut the traditional lump-sum clinic bill. Future Family's Femtech Insider profile framed the tie-up as a direct answer to "affordability barriers" that Cofertility has made visible. Kindbody's clinic footprint — roughly 30 sites across the U.S. as of 2025 — gives it the physical infrastructure to blend digital matching with in-person retrieval, a hybrid Cofertility cannot yet match.

OvaScience tells a different story. BioPharma Dive reported in 2024 that the company cut half its workforce after its core ovarian-rejuvenation technology failed to clear regulatory hurdles. The layoffs left OvaScience a fraction of its former headcount and removed a would-be innovator from the donor-egg supply chain. Its retreat underscores a sector split: companies with clinic networks and financing rails are doubling down, while pure-play biotech bets on egg-quality science are folding.

Cooper Companies, the sector's 800-pound gorilla, is managing its own upheaval. Stifel analysts noted in 2025 that CooperSurgical sale talks were progressing, and activist investor Jana Partners has pushed to break up the conglomerate, arguing the fertility unit would fetch a higher valuation standalone. Meanwhile, a Connecticut court approved a $272 million settlement from CooperSurgical over embryo-storage failures, a liability flashpoint that has made intended parents and clinics hypersensitive to cryopreservation logistics. The settlement, reported by CT Insider, did not name Cofertility but has accelerated due-diligence questions for any platform handling donor tissue.

The cryobank tier is consolidating around guarantees. California Cryobank's donor-egg bank announced a new guarantee program in 2025, promising intended parents a minimum number of mature eggs per cohort or a refund cycle. Generate Life Sciences, its parent, simultaneously expanded Canadian operations ahead of the Canadian Fertility Show. Fairfax Cryobank, a Generate rival, struck two parallel partnerships: one with IVI RMA North America to broaden donor-sperm access in the U.S., and another with Donor Network to push into key European markets. Both deals, announced via Business Wire and PR Newswire within months of each other, signal a race to lock up donor supply before split-model platforms like Cofertility siphon off high-AMH candidates.

Celmatix, once a data-analytics hopeful, pivoted to drug discovery. Gedeon Richter acquired its women's-health portfolio in 2025, per Femtech Insider, while Celmatix separately won a $3.5 million ARPA-H Sprint for Women's Health award and partnered with Brazil's Aché Laboratórios on PCOS therapeutics. The company also sued 23andMe for $100 million over alleged IP theft, a distraction that has kept it off the donor-egg marketplace entirely.

The pattern is clear: incumbents with physical infrastructure are layering financing and guarantees atop their clinic networks, while pure-tech or pure-science players are either exiting or retrenching. Cofertility's split model has forced the affordability conversation into the open — Kindbody's platform and Future Family's loans are the most visible replies — but the sector's response remains fragmented. No rival has yet replicated the split's core mechanic: a zero-cash egg-freeze cycle funded entirely by the donor's willingness to share half her yield. Until one does, the hiring surge in member outreach that Cofertility triggered will stay a one-company story.

Insurance Gaps and Regulatory Whiplash

The insurance picture remains thin. Only a quarter of companies with more than 200 employees cover IVF, and the procedure often carries no coverage at all, or partial reimbursement that still leaves patients facing roughly $20,000 per cycle. U.S. IVF costs run 271 percent above the average across 25 other countries, a gap that has persisted for years. Employers that do offer benefits typically structure them as capped lifetime maximums, not open-ended coverage. The Trump administration's October 2025 announcement encouraged employers to add fertility riders at fixed cost, similar to vision or dental plans, but stopped short of a mandate. Two people familiar with internal discussions told the Washington Post the White House does not plan to require insurers to cover IVF services, undercutting a key campaign pledge.

Regulatory whiplash has added uncertainty. In early 2024 the Alabama Supreme Court ruled that frozen embryos are children and that destroying them can trigger wrongful-death liability. Clinics in the state paused services; patients scrambled to move embryos out of state. Trump publicly urged the Alabama Legislature to protect IVF access and later issued an executive order promising a detailed cost-reduction report by late May 2025. That report has not been released. Meanwhile, federal programs that let patients compare clinic success rates, monitor lab safety, and interpret health data have been scaled back, a move maternal-health experts say will degrade transparency for years.

The drug-cost flank moved faster. In October 2025 Trump struck a deal with EMD Serono, the world's largest fertility-drug maker, to cut prices on key medications, including Gonal-f, the standard stimulation injectable, in exchange for relief from planned pharmaceutical tariffs. EMD Serono sold those drugs directly to patients through a new federal portal, TrumpRx.gov, launched January 2026. The arrangement bypasses traditional pharmacy benefit managers, but it covers only a slice of the total IVF bill: medication typically accounts for 20 to 30 percent of cycle cost. Lab fees, monitoring, anesthesia, and embryo storage remain uncapped.

Public opinion is settled. A Pew Research Center poll from April 2024 found seven in 10 U.S. adults say IVF access is a good thing, with only modest partisan splits. That consensus has not translated into federal coverage mandates, but it has fueled private-market growth. The hiring signal is clear: companies building direct-to-consumer fertility marketplaces, remote care-navigation teams, and clinic-software layers are adding headcount in member outreach, clinical operations, and regulatory affairs, roles that barely existed five years ago.

Makler's split model began as a workaround for a broken insurance system. It has become a stress test for every incumbent's cost structure. The next funding round will show whether the workaround can scale into a standard, or whether the sector's next move is a consolidation that buries the split inside a clinic network's guarantee.

Working in frontier tech? Zero G Talent tracks the openings: see every open ASML role, browse frontier tech jobs, openings at Stripe, and the people building the field.